Eikon Therapeutics outlined plans to go public after raising more than $1 billion in private funding since 2019 and building a drug portfolio from dealmaking and its protein-motion platform. Run by former Merck executives including Roger Perlmutter and Roy Baynes, Eikon has four programs in human testing; its lead asset EIK1001 is in a Phase 2/3 trial in advanced melanoma with an interim analysis expected later this year. The company said it will use Nobel‑derived microscopy technology to probe protein dynamics and has licensed several clinical programs to accelerate the pipeline.